GPER Mediates Estrogen-Induced Signaling and Proliferation in Human Breast Epithelial Cells and Normal and Malignant Breast

Hormones and Cancer

Volumn 5, Issue 3, 2014, Pages 146-160

  Scaling, Allison L ^a,b,c   Prossnitz, Eric R ^a,c   Hathaway, Helen J ^a,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; G PROTEIN COUPLED RECEPTOR 30; HEPARIN; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; BREAST REDUCTION; CANCER CELL; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; ESTROGEN ACTIVITY; EX VIVO STUDY; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MASTECTOMY; MITOSIS INDEX; MORPHOGENESIS; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; BREAST; BREAST TUMOR; CYTOLOGY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; ESTRADIOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MITOTIC INDEX; PHOSPHORYLATION; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84900437591     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0174-1     Document Type: Article

References (83)

1. Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V et al (2006) Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat 99(1): 23-33. doi: 10. 1007/s10549-006-9177-0.
2. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI et al (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67(4): 1859-1866.
3. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N et al (2010) GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat 123(1): 51-58. doi: 10. 1007/s10549-009-0631-7.
4. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA et al (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70(3): 1184-1194.
5. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E (2001) Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61(18): 6747-6754.
6. Bernstein L (2002) Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7(1): 3-15.
7. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA et al (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2(4): 207-212.
8. Brisken C, O'Malley B (2010) Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2(12): a003178.
9. Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40(1): 2-11.
10. Buxant F, Engohan-Aloghe C, Noel JC (2010) Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol 18(3): 254-257. doi: 10. 1097/PAI. 0b013e3181c10180.
11. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10): 4831-4842.
12. Cheskis BJ, Greger JG, Nagpal S, Freedman LP (2007) Signaling by estrogens. J Cell Physiol 213(3): 610-617. doi: 10. 1002/jcp. 21253.
13. Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn J (1999) Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat 55(3): 267-283.
14. Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57(22): 4987-4991.
15. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4): 276-285. doi: 10. 1056/NEJM200101253440407.
16. Couse JF, Korach KS (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20(3): 358-417.
17. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11(14): 2756-2761. doi: 10. 4161/cc. 21195.
18. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30(3): 256-268.
19. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG et al (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5(6): 421-427.
20. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI et al (2011) Identification of a GPER/GPR30 antagonist with improved estrogen receptor counter selectivity. J Steroid Biochem Mol Biol 127(3-5): 358-366.
21. Dong J, Opresko LK, Chrisler W, Orr G, Quesenberry RD, Lauffenburger DA, Wiley HS (2005) The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode. Mol Biol Cell 16(6): 2984-2998.
22. Eigeliene N, Harkonen P, Erkkola R (2006) Effects of estradiol and medroxyprogesterone acetate on morphology, proliferation and apoptosis of human breast tissue in organ cultures. BMC Cancer 6: 246.
23. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18): 3808-3816.
24. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E et al (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106(46): 19503-19508.
25. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12(21): 6359-6366.
26. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14(10): 1649-1660.
27. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B (1998) Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69(5): 963-969.
28. Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson JA (2002) Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 99(24): 15578-15583. doi: 10. 1073/pnas. 192561299.
29. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73(11): 1039-1051.
30. Frame MC (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602(2): 114-130.
31. Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86(3-5): 245-253.
32. Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6(5): 213-218. doi: 10. 1186/bcr921.
33. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA (2005) Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24(44): 6605-6616.
34. Jala VR, Radde BN, Haribabu B, Klinge CM (2012) Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer 12: 624. doi: 10. 1186/1471-2407-12-624.
35. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, Wolczynski S (2005) Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 41(18): 2924-2934. doi: 10. 1016/j. ejca. 2005. 09. 010.
36. Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 98(26): 15197-15202. doi: 10. 1073/pnas. 211556298.
37. Kolkova Z, Noskova V, Ehinger A, Hansson S, Casslen B (2010) G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Mol Hum Reprod 16(10): 743-751. doi: 10. 1093/molehr/gaq043.
38. Korach KS (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266(5190): 1524-1527.
39. Kuo L, Chang HC, Leu TH, Maa MC, Hung WC (2006) Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 207(3): 729-734. doi: 10. 1002/jcp. 20616.
40. Kuo WH, Chang LY, Liu DL, Hwa HL, Lin JJ, Lee PH, Chen CN et al (2007) The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan J Obstet Gynecol 46: 135-145.
41. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142(9): 4120-4130.
42. Levin ER (2002) Cellular functions of plasma membrane estrogen receptors. Steroids 67(6): 471-475.
43. Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17(3): 309-317. doi: 10. 1210/me. 2002-0368.
44. Lin CY, Strom A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB et al (2007) Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 9(2): R25.
45. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67(2): 111-116.
46. Lostumbo A, Mehta D, Setty S, Nunez R (2006) Flow cytometry: a new approach for the molecular profiling of breast cancer. Exp Mol Pathol 80(1): 46-53.
47. Luo HJ, Luo P, Yang GL, Peng QL, Liu MR, Tu G (2011) G-protein coupled estrogen receptor 1 expression in primary breast cancers and its correlation with clinicopathological variables. J Breast Cancer 14(3): 185-190. doi: 10. 4048/jbc. 2011. 14. 3. 185.
48. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S (2004) The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279(26): 27008-27016. doi: 10. 1074/jbc. M403588200.
49. McBryan J, Howlin J, Napoletano S, Martin F (2008) Amphiregulin: role in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 13(2): 159-169. doi: 10. 1007/s10911-008-9075-7.
50. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A, Nanayakkara M et al (2006) Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 1089: 194-200.
51. Milligan G, Canals M, Pediani JD, Ellis J, Lopez-Gimenez JF (2006) The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc 2: 145-161.
52. Moss ML, Rasmussen FH (2007) Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 366(2): 144-148.
53. Naglich JG, Metherall JE, Russell DW, Eidels L (1992) Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69(6): 1051-1061.
54. Ordonez-Moran P, Munoz A (2009) Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 8(11): 1675-1680.
55. Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G et al (2009) GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 80(1): 34-41.
56. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G et al (2008) G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149(10): 4846-4856.
57. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28(5): 523-532.
58. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1): 423-428.
59. Pedram A, Razandi M, Levin ER (2006) Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20(9): 1996-2009.
60. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1): 17-35.
61. Pilat MJ, Christman JK, Brooks SC (1996) Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6. Breast Cancer Res Treat 37(3): 253-266.
62. Razandi M, Pedram A, Park ST, Levin ER (2003) Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278(4): 2701-2712. doi: 10. 1074/jbc. M205692200.
63. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307(5715): 1625-1630.
64. Rios CD, Jordan BA, Gomes I, Devi LA (2001) G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 92(2-3): 71-87.
65. Sanden C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Martensson UE, Olde B, Leeb-Lundberg LM (2011) G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol Pharmacol 79(3): 400-410.
66. Sharma G, Prossnitz ER (2011) Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 152(8): 3030-3039.
67. Sotoca AM, Ratman D, van der Saag P, Strom A, Gustafsson JA, Vervoort J, Rietjens IM, Murk AJ (2008) Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol 112(4-5): 171-178.
68. Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L, Murphy G (1998) The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 111(Pt 18): 2789-2798.
69. Sutherland RL, Prall OW, Watts CK, Musgrove EA (1998) Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3(1): 63-72.
70. Takemura T, Kondo S, Homma T, Sakai M, Harris RC (1997) The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells. J Biol Chem 272(49): 31036-31042.
71. Tan H, Zhong Y, Pan Z (2009) Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines. BMC Cancer 9: 31.
72. Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146(2): 624-632.
73. Treeck O, Lattrich C, Springwald A, Ortmann O (2010) Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 120(3): 557-565. doi: 10. 1007/s10549-009-0413-2.
74. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20(3): 631-646.
75. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103(24): 9063-9068. doi: 10. 1073/pnas. 0603339103.
76. Wei Y, Mizzen CA, Cook RG, Gorovsky MA, Allis CD (1998) Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci U S A 95(13): 7480-7484.
77. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27(7): 1019-1032.
78. Willmarth NE, Ethier SP (2006) Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 281(49): 37728-37737.
79. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3): 270-282.
80. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC (2000) Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6(5): 2028-2036.
81. Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12(1): 9-18. doi: 10. 1038/sj. cr. 7290105.
82. Zhang X, Ding L, Kang L, Wang ZY (2012) Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One 7(1): e30174. doi: 10. 1371/journal. pone. 0030174.
83. Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y (2006) Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 29(1): 269-278.